Ratings by Mizuho (Vamil Divan)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/3/2026 | Evolus | EOLS | Maintain | Outperform (N/A) |
|
Details | ||
| 12/12/2025 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 12/11/2025 | Evolus | EOLS | Maintain | Outperform (N/A) |
|
Details | ||
| 12/4/2025 | Evolus | EOLS | Maintain | Outperform (N/A) |
|
Details | ||
| 12/1/2025 | Evolus | EOLS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/13/2025 | Alkermes | ALKS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/13/2025 | Evolus | EOLS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/6/2025 | Evolus | EOLS | Maintain | Outperform (N/A) |
|
Details | ||
| 10/29/2025 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 10/27/2025 | Alkermes | ALKS | Maintain | Outperform (N/A) |
|
Details | ||
| 10/8/2025 | Alkermes | ALKS | Maintain | Outperform (Outperform) |
|
Details | ||
| 8/21/2025 | Evolus | EOLS | Maintain | Outperform (Outperform) |
|
Details | ||
| 8/21/2025 | Evolus | EOLS | Maintain | Outperform (N/A) |
|
Details | ||
| 8/6/2025 | Evolus | EOLS | Maintain | Outperform (N/A) |
|
Details | ||
| 7/31/2025 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 5/28/2025 | Evolus | EOLS | Maintain | Outperform (N/A) |
|
Details | ||
| 1/30/2025 | Revance Therapeutic | RVNC | Maintain | Neutral (N/A) |
|
Details | ||
| 1/30/2025 | Revance Therapeutic | RVNC | Maintain | Neutral (N/A) |
|
Details | ||
| 1/30/2025 | Sage Therapeutics | SAGE | Maintain | Neutral (N/A) |
|
Details | ||
| 1/22/2025 | Revance Therapeutic | RVNC | Maintain | Neutral (N/A) |
|
Details | ||
| 12/12/2024 | Sage Therapeutics | SAGE | Maintain | Neutral (N/A) |
|
Details | ||
| 12/10/2024 | Revance Therapeutic | RVNC | Maintain | Neutral (N/A) |
|
Details | ||
| 11/13/2024 | Alkermes | ALKS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2024 | Relmada Therapeutics Inc | RLMD | Maintain | Outperform (N/A) |
|
Details | ||
| 10/30/2024 | Sage Therapeutics | SAGE | Maintain | Neutral (N/A) |
|
Details | ||
| 10/1/2024 | Alkermes | ALKS | Maintain | Outperform (Outperform) |
|
Details | ||
| 10/1/2024 | Alkermes | ALKS | Maintain | Outperform (N/A) |
|
Details | ||
| 9/27/2024 | Neurocrine Bio. | NBIX | Maintain | Neutral (Neutral) |
|
Details | ||
| 9/26/2024 | Alkermes | ALKS | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/26/2024 | Alkermes | ALKS | Maintain | Outperform (N/A) |
|
Details | ||
| 9/17/2024 | Revance Therapeutic | RVNC | Maintain | Neutral (Neutral) |
|
Details | ||
| 9/13/2024 | Evolus | EOLS | Maintain | Outperform (N/A) |
|
Details | ||
| 9/12/2024 | Relmada Therapeutics Inc | RLMD | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/10/2024 | Alkermes | ALKS | Maintain | Outperform (N/A) |
|
Details | ||
| 9/9/2024 | Evolus | EOLS | Maintain | Outperform (Outperform) |
|
Details | ||
| 8/21/2024 | Evolus | EOLS | Maintain | Outperform (N/A) |
|
Details | ||
| 8/13/2024 | Revance Therapeutic | RVNC | Maintain | Neutral (N/A) |
|
Details | ||
| 8/1/2024 | Sage Therapeutics | SAGE | Maintain | Neutral (N/A) |
|
Details | ||
| 7/25/2024 | Sage Therapeutics | SAGE | Maintain | Neutral (N/A) |
|
Details | ||
| 7/19/2024 | Sage Therapeutics | SAGE | Maintain | Neutral (N/A) |
|
Details | ||
| 5/10/2024 | Revance Therapeutic | RVNC | Maintain | Neutral (N/A) |
|
Details | ||
| 4/26/2024 | Sage Therapeutics | SAGE | Maintain | Neutral (Neutral) |
|
Details | ||
| 4/17/2024 | Sage Therapeutics | SAGE | Maintain | Neutral (N/A) |
|
Details | ||
| 4/9/2024 | Alkermes | ALKS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/8/2024 | Evolus | EOLS | Maintain | Outperform (N/A) |
|
Details | ||
| 2/8/2024 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 1/29/2024 | Revance Therapeutic | RVNC | Downgrade | Neutral (Outperform) |
5.93 (3.65) |
-38.45% | Details | |
| 1/26/2024 | Karuna Therapeutics Inc. | KRTX | Downgrade | Neutral (Outperform) |
315.15 (329.83) |
4.66% | Details | |
| 11/22/2023 | Revance Therapeutic | RVNC | Maintain | Outperform (N/A) |
|
Details | ||
| 11/13/2023 | Karuna Therapeutics Inc. | KRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/13/2023 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 11/10/2023 | Neurocrine Bio. | NBIX | Maintain | (N/A) |
|
Details | ||
| 11/2/2023 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 10/26/2023 | Alkermes | ALKS | Maintain | Outperform (N/A) |
|
Details | ||
| 10/17/2023 | Alkermes | ALKS | Maintain | Outperform (N/A) |
|
Details | ||
| 9/7/2023 | Sage Therapeutics | SAGE | Maintain | Neutral (N/A) |
|
Details | ||
| 8/21/2023 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/10/2023 | Relmada Therapeutics Inc | RLMD | Maintain | Outperform (N/A) |
|
Details | ||
| 8/8/2023 | Sage Therapeutics | SAGE | Maintain | Neutral (N/A) |
|
Details | ||
| 8/4/2023 | Karuna Therapeutics Inc. | KRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/2/2023 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 6/7/2023 | Revance Therapeutic | RVNC | Maintain | Outperform (N/A) |
|
Details | ||
| 6/7/2023 | Evolus | EOLS | Maintain | Outperform (N/A) |
|
Details | ||
| 6/7/2023 | Alkermes | ALKS | Maintain | Outperform (N/A) |
|
Details | ||
| 5/8/2023 | Karuna Therapeutics Inc. | KRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/4/2023 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 4/27/2023 | Alkermes | ALKS | Maintain | Outperform (N/A) |
|
Details | ||
| 4/11/2023 | Alkermes | ALKS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/15/2023 | Revance Therapeutic | RVNC | Maintain | Outperform (N/A) |
|
Details | ||
| 3/14/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 2/28/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 2/17/2023 | Sage Therapeutics | SAGE | Maintain | Neutral (N/A) |
|
Details | ||
| 1/19/2023 | Evolus | EOLS | Maintain | Outperform (N/A) |
|
Details | ||
| 12/21/2022 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 12/9/2022 | Karuna Therapeutics Inc. | KRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/22/2022 | Alkermes | ALKS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/15/2022 | Satsuma Pharmaceuticals | STSA | Downgrade | Neutral (Outperform) |
4.05 (1.10) |
-72.84% | Details | |
| 11/2/2022 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 10/20/2022 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 10/7/2022 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 8/9/2022 | Karuna Therapeutics Inc. | KRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/9/2022 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 8/8/2022 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/3/2022 | Evolus | EOLS | Maintain | Outperform (Outperform) |
|
Details | ||
| 7/28/2022 | Alkermes | ALKS | Maintain | Outperform (N/A) |
|
Details | ||
| 6/15/2022 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 6/6/2022 | Eli Lilly | LLY | Maintain | Outperform (Outperform) |
|
Details | ||
| 5/26/2022 | Karuna Therapeutics Inc. | KRTX | Maintain | Outperform (Outperform) |
|
Details | ||
| 5/25/2022 | Cabaletta Bio Inc. | CABA | Maintain | Outperform (Outperform) |
|
Details | ||
| 5/17/2022 | ContraFect Corp. | CFRX | Maintain | Outperform (Outperform) |
|
Details | ||
| 5/13/2022 | Satsuma Pharmaceuticals | STSA | Maintain | Outperform (N/A) |
|
Details | ||
| 5/12/2022 | Revance Therapeutic | RVNC | Maintain | Outperform (Outperform) |
|
Details | ||
| 5/4/2022 | Pfizer | PFE | Maintain | Neutral (Neutral) |
|
Details | ||
| 5/4/2022 | Sage Therapeutics | SAGE | Maintain | Outperform (Outperform) |
|
Details | ||
| 5/3/2022 | Axsome Therapeutics | AXSM | Maintain | Outperform (N/A) |
|
Details | ||
| 5/2/2022 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 4/28/2022 | Eli Lilly | LLY | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/27/2022 | Alkermes | ALKS | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/27/2022 | Karuna Therapeutics Inc. | KRTX | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/26/2022 | Neurocrine Bio. | NBIX | Maintain | Neutral (Neutral) |
|
Details | ||
| 4/26/2022 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (Neutral) |
|
Details | ||
| 4/22/2022 | Alkermes | ALKS | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/19/2022 | Axsome Therapeutics | AXSM | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/19/2022 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (Neutral) |
|
Details | ||
| 4/18/2022 | Magenta Therapeutics | MGTA | Maintain | Outperform (N/A) |
|
Details | ||
| 4/14/2022 | Magenta Therapeutics | MGTA | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/14/2022 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 3/29/2022 | Axsome Therapeutics | AXSM | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/18/2022 | Cabaletta Bio Inc. | CABA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/16/2022 | Satsuma Pharmaceuticals | STSA | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/16/2022 | Xeris Pharmaceuticals | XERS | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/9/2022 | Relmada Therapeutics Inc | RLMD | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/8/2022 | Revance Therapeutic | RVNC | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/4/2022 | Evolus | EOLS | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/3/2022 | Sage Therapeutics | SAGE | Maintain | Neutral (N/A) |
|
Details | ||
| 3/3/2022 | Karuna Therapeutics Inc. | KRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2022 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2022 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 2/23/2022 | Relmada Therapeutics Inc | RLMD | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/14/2022 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 2/10/2022 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 2/4/2022 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 2/4/2022 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 1/5/2022 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 1/5/2022 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 12/21/2021 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 12/14/2021 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 12/7/2021 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 12/2/2021 | Zogenix, Inc. | ZGNX | New Coverage | Outperform (N/A) |
11.25 (26.68) |
137.16% | Details | |
| 12/2/2021 | Xeris Pharmaceuticals | XERS | New Coverage | Outperform (N/A) |
2.09 (5.81) |
177.99% | Details | |
| 12/2/2021 | Magenta Therapeutics | MGTA | New Coverage | Outperform (N/A) |
5.63 (0.70) |
-87.57% | Details | |
| 12/2/2021 | Concert Pharmaceuticals | CNCE | New Coverage | Outperform (N/A) |
3.38 (8.37) |
147.63% | Details | |
| 11/18/2021 | Biohaven Pharmaceutical Holding | BHVN | Maintain | (N/A) |
|
Details | ||
| 11/18/2021 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/18/2021 | Sage Therapeutics | SAGE | Maintain | Neutral (N/A) |
|
Details | ||
| 11/18/2021 | Axsome Therapeutics | AXSM | Maintain | Outperform (N/A) |
|
Details | ||
| 11/18/2021 | Relmada Therapeutics Inc | RLMD | New Coverage | Outperform (N/A) |
21.87 (2.77) |
-87.33% | Details | |
| 11/15/2021 | ContraFect Corp. | CFRX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/9/2021 | Alkermes | ALKS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/4/2021 | Karuna Therapeutics Inc. | KRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/4/2021 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 11/2/2021 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 11/1/2021 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 10/27/2021 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 9/10/2021 | Alkermes | ALKS | Maintain | Outperform (N/A) |
|
Details | ||
| 9/1/2021 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 8/30/2021 | Cabaletta Bio Inc. | CABA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/23/2021 | Axsome Therapeutics | AXSM | Maintain | Outperform (N/A) |
|
Details | ||
| 8/10/2021 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/10/2021 | Axsome Therapeutics | AXSM | Maintain | Outperform (N/A) |
|
Details | ||
| 8/5/2021 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 8/4/2021 | Sage Therapeutics | SAGE | Maintain | Neutral (N/A) |
|
Details | ||
| 8/4/2021 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/4/2021 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 8/2/2021 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 7/30/2021 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 7/29/2021 | Alkermes | ALKS | Maintain | Outperform (N/A) |
|
Details | ||
| 7/12/2021 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
| 6/30/2021 | Cabaletta Bio Inc. | CABA | New Coverage | Outperform (N/A) |
8.08 (3.17) |
-60.77% | Details | |
| 6/24/2021 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 6/22/2021 | Sage Therapeutics | SAGE | Maintain | Neutral (N/A) |
|
Details | ||
| 6/22/2021 | Satsuma Pharmaceuticals | STSA | Upgrade | Outperform (Neutral) |
5.62 (1.10) |
-80.43% | Details | |
| 6/15/2021 | Sage Therapeutics | SAGE | Maintain | Outperform (N/A) |
|
Details | ||
| 5/28/2021 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/11/2021 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2021 | Pfizer | PFE | Downgrade | Neutral (Outperform) |
39.95 (27.05) |
-32.29% | Details | |
| 5/6/2021 | Evolus | EOLS | Upgrade | Outperform (Neutral) |
9.01 (5.53) |
-38.62% | Details | |
| 5/5/2021 | Sage Therapeutics | SAGE | Maintain | Neutral (N/A) |
|
Details | ||
| 5/3/2021 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 4/28/2021 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 4/26/2021 | Axsome Therapeutics | AXSM | Maintain | Outperform (N/A) |
|
Details | ||
| 4/26/2021 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 4/26/2021 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/26/2021 | Alkermes | ALKS | Maintain | Outperform (N/A) |
|
Details | ||
| 4/12/2021 | Sage Therapeutics | SAGE | Maintain | Neutral (N/A) |
|
Details | ||
| 4/6/2021 | Acadia Pharmaceuticals | ACAD | Downgrade | Neutral (Outperform) |
25.59 (22.16) |
-13.4% | Details | |
| 4/5/2021 | Satsuma Pharmaceuticals | STSA | Maintain | Neutral (N/A) |
|
Details | ||
| 4/1/2021 | ContraFect Corp. | CFRX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/31/2021 | ContraFect Corp. | CFRX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/30/2021 | Evolus | EOLS | Maintain | Neutral (N/A) |
|
Details | ||
| 3/17/2021 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 3/12/2021 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 3/8/2021 | Eli Lilly | LLY | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/2/2021 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/2/2021 | Axsome Therapeutics | AXSM | Maintain | Outperform (N/A) |
|
Details | ||
| 3/1/2021 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 2/26/2021 | Karuna Therapeutics Inc. | KRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/26/2021 | Sage Therapeutics | SAGE | Downgrade | Neutral (Outperform) |
85.04 (8.68) |
-89.79% | Details | |
| 2/5/2021 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 2/4/2021 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 2/3/2021 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 2/1/2021 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 1/18/2021 | Eli Lilly | LLY | Upgrade | Outperform (Neutral) |
186.69 (990.33) |
430.47% | Details | |
| 1/7/2021 | Alkermes | ALKS | Maintain | Outperform (N/A) |
|
Details | ||
| 12/17/2020 | Sage Therapeutics | SAGE | Maintain | Outperform (N/A) |
|
Details | ||
| 12/16/2020 | Eli Lilly | LLY | Maintain | Neutral (N/A) |
|
Details | ||
| 12/16/2020 | Axsome Therapeutics | AXSM | New Coverage | Outperform (N/A) |
79.95 (60.79) |
-23.96% | Details | |
| 12/16/2020 | Acadia Pharmaceuticals | ACAD | New Coverage | Outperform (N/A) |
52.13 (22.16) |
-57.49% | Details | |
| 12/4/2020 | Sage Therapeutics | SAGE | Upgrade | Outperform (Neutral) |
68.57 (8.68) |
-87.34% | Details | |
| 11/13/2020 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/12/2020 | Pfizer | PFE | Maintain | Outperform (Outperform) |
|
Details | ||
| 11/11/2020 | Satsuma Pharmaceuticals | STSA | Maintain | Neutral (N/A) |
|
Details | ||
| 11/6/2020 | Sage Therapeutics | SAGE | Maintain | Neutral (N/A) |
|
Details | ||
| 10/15/2020 | Alkermes | ALKS | Upgrade | Outperform (Neutral) |
17.27 (28.63) |
65.78% | Details | |
| 8/19/2020 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 7/23/2020 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 7/20/2020 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 7/7/2020 | Evolus | EOLS | Downgrade | Neutral (Outperform) |
5.32 (5.53) |
3.95% | Details | |
| 7/1/2020 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 6/24/2020 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
| 6/10/2020 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 6/10/2020 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
| 6/4/2020 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 5/22/2020 | Evolus | EOLS | Maintain | Outperform (N/A) |
|
Details | ||
| 5/18/2020 | Pfizer | PFE | Maintain | Outperform (Outperform) |
|
Details | ||
| 5/6/2020 | Abbvie | ABBV | Maintain | Outperform (Outperform) |
|
Details | ||
| 5/4/2020 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 4/27/2020 | Pfizer | PFE | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/22/2020 | Eli Lilly | LLY | Maintain | Neutral (Neutral) |
|
Details | ||
| 3/18/2020 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 2/11/2020 | Eli Lilly | LLY | Maintain | Neutral (Neutral) |
|
Details | ||
| 2/11/2020 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/10/2020 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/10/2020 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/10/2020 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 2/6/2020 | Neurocrine Bio. | NBIX | New Coverage | Neutral (N/A) |
103.10 (128.13) |
24.28% | Details | |
| 2/6/2020 | Pfizer | PFE | New Coverage | Outperform (N/A) |
37.69 (27.05) |
-28.23% | Details | |
| 2/6/2020 | Evolus | EOLS | New Coverage | Outperform (N/A) |
10.39 (5.53) |
-46.78% | Details | |
| 2/6/2020 | Sage Therapeutics | SAGE | New Coverage | Neutral (N/A) |
67.28 (8.68) |
-87.1% | Details | |
| 2/6/2020 | Biohaven Pharmaceutical Holding | BHVN | New Coverage | Outperform (N/A) |
52.44 (9.92) |
-81.08% | Details | |
| 2/6/2020 | Alkermes | ALKS | New Coverage | Neutral (N/A) |
17.52 (28.63) |
63.41% | Details | |
| 2/6/2020 | Abbvie | ABBV | New Coverage | Outperform (N/A) |
84.36 (230.11) |
172.77% | Details | |
| 2/6/2020 | Karuna Therapeutics Inc. | KRTX | New Coverage | Outperform (N/A) |
93.02 (329.83) |
254.58% | Details | |
| 2/5/2020 | Eli Lilly | LLY | New Coverage | Neutral (N/A) |
143.44 (186.69) |
30.15% | Details |
